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Background
A phase II trial of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxoru-
bicin and rituximab (DA-EPOCH-R) from the National Cancer Institute showed promising
activity in untreated diffuse large B-cell lymphoma.  The Cancer and Leukemia Group B con-
ducted a study to determine if these results could be reproduced in a multi-institutional setting.  
Design and Methods
The study included 69 patients with untreated diffuse large B-cell lymphoma at least 18 years
of age and at least stage II.  Radiaton therapy was not permitted on study. Median age was 58
years (range 23-83) and 40% had high-intermediate or high International Prognostic Index risk.
Immunohistochemical biomarkers for cell of origin and proliferation were performed. 
Results
With a median follow up of 62 months, time to progression and overall survival were 81% and
84%, respectively, and time to progression was 87%, 92% and 54% for low/low-intermediate,
high-intermediate and high International Prognostic Index risk groups, respectively, at 5-years
and beyond.  The time to progression and event-free survival of germinal center B-cell lym-
phoma were 100% and 94%, respectively, and non-germinal center B-cell GCB diffuse large B-
cell lymphoma were 67% and 58%, respectively, at 62 months (germinal center vs. non-germi-
nal center B cell P=0.008).  DA-EPOCH-R was tolerated without significant grade 4 non-hema-
tologic toxicities. 
Conclusions
These results provide the first confirmation by a multi-institutional group that DA-EPOCH-R
provides high durable remissions in diffuse large B-cell lymphoma and is effective in both ger-
minal center and non-germinal center B-cell subtypes. The trial was registered at ClinicalTrials.Gov
(NCT00032019).
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Introduction
Over the past 30 years, efforts to improve chemotherapy
strategies for diffuse large B-cell lymphoma (DLBCL) have
met with limited success.1-3 While modifications of CHOP
chemotherapy led to modest improvements in outcome,
these were generally overcome by the addition of ritux-
imab.4,5 Alternative regimens based on aggressive treatment
platforms such as ACVBP have improved outcomes in
select patient groups, even in the rituximab era, but their
applicability is restricted to younger patients due to high
acute and long-term toxicities.6-9 The bases for these strate-
gies have generally come from the hypothesis that 'non-
cross resistant' drugs and dose intensity will overcome drug
resistance, but this has not generally been borne out.10, 11 It
is now recognized that treatment failure depends on a com-
plex interplay of factors including tumor biology, tumor
volume, pharmacokinetics, and pharmacogenomics.10
Investigators at the National Cancer Institute (NCI) pur-
sued a therapeutic strategy that drew on concepts of drug
resistance and pharmacokinetics. Based on studies that
showed high tumor proliferation is an adverse prognostic
factor in DLBCL, they modeled the effect of drug schedule
on tumor cell kill and showed that continuous low-dose
drug exposure enhances cell kill of rapidly proliferating
tumor cells in vitro.12-14 Furthermore, they hypothesized
that variations in drug clearance among patients would
significantly impact the drug concentration-response
curve in the setting of low steady state concentrations
(Css) that are achieved during prolonged continuous infu-
sion schedules. These concepts formed the basis for the
dose adjusted (DA)-EPOCH regimen in which doxoru-
bicin, vincristine and etoposide are infused over 96 h,
cyclophosphamide and prednisone are administered on a
bolus schedule, and doxorubicin, etoposide and
cyclophosphamide are pharmacodynamically dose-adjust-
ed based on the neutrophil nadir.15-18 The NCI initially per-
formed a phase II study of DA-EPOCH followed by a
study of DA-EPOCH with rituximab in untreated DLBCL,
both of which performed well compared to reported out-
comes with CHOP and R-CHOP, respectively, in similar
patient groups.2-5,17,19 To determine whether the results of
the NCI DA-EPOCH-R study were robust and could be
translated into the community setting, the Cancer and
Leukemia Group B study group (CALGB) performed an
independent multi-institutional study of DA-EPOCH-R
with analysis of molecular subtype. 
Design and Methods
Study design 
This multi-center phase II study of DA-EPOCH-R in untreated
de novoCD20+ DLBCL enrolled patients at 18 institutions between
15 February 2002 and 28 May 2004. To assure an independent
assessment of DA-EPOCH-R, the NCI did not enroll patients on
this multicenter study. The minimum follow up required for each
patient was three years or until death, whichever occurred first.
Data collection was stopped on 15 April 2009 once this time point
had been reached. Clinical objectives included response rate, time
to progression free and overall survival and toxicity, and experi-
mental end points included tumor immunohistochemical (IHC)
biomarker analysis. Seventy-eight patients were enrolled, of
which 9 were ineligible; 2 did not start protocol treatment, one
patient was taken off study on day one due to rituximab intoler-
ance, one patient refused treatment after one cycle, and 5 patients
had ineligible histologies. Central pathology review was conduct-
ed by EH in 62 patients. 
Eligibility criteria included stages II-IV, human immunodeficien-
cy virus (HIV) negative, negative pregnancy test, adequate major
organ function, no central nervous system (CNS) lymphoma, and
no evidence of low-grade lymphoma.15,17 Initial evaluation includ-
ed standard blood tests, whole body computed tomography (CT),
and bone marrow biopsy. Standard staging and response criteria
were used.20,21 Disease sites were restaged after cycles 4, 6 and 8
(if administered). The study was approved by the Institutional
Review Boards of all participating institutions and complied with
the Declaration of Helsinki. All patients gave written informed
consent. All authors had access to the primary data and approved
the manuscript. 
Chemotherapy and dose adjustments
DA-EPOCH-R was administered as previously described.15, 17
Patients received 2 cycles beyond CR or stable changes for a min-
imum of 6 and a maximum of 8 cycles. Pharmacodynamic dose
adjustment was based on twice weekly complete blood counts to
achieve limited absolute neutropenia count (ANC) below 500/μL
with the administration of filgrastim 300 mg from Day 5 until the
ANC reached over 5000/μL past the nadir counts.15,17 Strict adher-
ence to the dose adjustment paradigm is mandatory to achieve the
results reported herein. Patients with more than one extranodal
site and elevated LDH and/or bone marrow involvement by
DLBCL received CNS prophylaxis consisting of intrathecal
methotrexate 12 mg given on Day 1 (or Day 2) of cycles 3, 4, 5,
and 6. Radiation therapy was not permitted on study. Bactrim®
DS was administered twice daily for three days per week.
Biomarkers 
Immunostaining on whole tissue sections with appropriate pri-
mary antibodies was performed at the Pathology Coordinating
Office of the CALGB (CD10, clone 56C6; BCL6, PG-B6p; MUM1,
clone MUM1p; BCL2, clone 124; Ki67, clone MIB1) using auto-
mated immunostainers (Dako, Carpenteria, CA, USA). High pH
(9.0) antigen retrieval (Dako) was used for BCL6 and MUM1 while
low pH (6.1) was used for CD10, BCL2, and Ki67. LMO2 (clone
1A9-1) was performed at the Cleveland Clinic (Benchmark XT,
Ventana Medical Systems, Tucson, AZ, USA). Slides were scored
independently in 10% increments by 2 pathologists, with a third
review in case of over 20% disagreement for all immunostains
(mean score used as final value) except Ki67, for which image
analysis (IA, Aperio, Scanscope) and a visual estimate (0=<10%,
1+=10-24%, 2+=25-49%, 3+=50-74%, 4+=75-100%) was used. A
30% cut off for positive staining was used for CD10, BCL6,
MUM1 and BCL2 and 60% for Ki67. Classification of tumor biop-
sies into GCB or non-GCB (i.e. ABC surrogate) subtypes was
determined using CD10, BCL6, and MUM1 IHC markers by the
validated method of Hans et al.22
Statistical analysis
Overall (OS), time to progression (TTP) and event-free (EFS) sur-
vivals were calculated using the Kaplan-Meier method and the sig-
nificance between Kaplan-Meier curves was calculated using log
rank procedure.23,24 Survival end points were calculated from on-
study date until death, relapse, progression or last follow up as
appropriate. For TTP, deaths among patients without progression
or relapse were censored. International Prognostic Index score (IPI)
could not be determined in 2 patients due to missing data. Follow
up was calculated from study entry until death or close of study
analysis for each patient. The analysis of biomarkers was not
adjusted for multiple comparisons as these were pre-specified.15
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The SAS v9.2 (Cary, NC, USA) statistical package was used for
analyses. Patient registration and data collection were managed by
the CALGB Statistical Center. Data quality was ensured by careful
review of data by CALGB Statistical Center staff and by the study
chairperson. CALGB statisticians performed all statistical analyses.
Results
Clinical characteristics and outcome
Sixty-nine eligible patients with untreated DLBCL were
enrolled (Table 1). Median age was 58 years (range 23-83);
59% were in advanced stage, 72% had an elevated serum
lactate dehydrogenase (LDH) level, and 40% had high-
intermediate/high risk IPI scores.25 Overall, 58 (84%)
patients achieved a complete response (CR), which
includes those with CR unconfirmed, and 10 (15%)
achieved a partial response (PR). Ten (17%) of those
achieving CR and 3 (30%) of those achieving PR have
relapsed, half of these relapsed patients had high IPI
scores. All episodes of disease progression except one
occurred within the first 1.6 years. 
The median (range) follow up of living patients is 5.2
(3.4-6.8) years. At 5-years and beyond, the TTP, EFS and
OS are 81%, 75% and 84%, respectively (Figure 1A-C).
Three patients died without progression, one on treat-
ment and 2 during follow up from respiratory and cardiac
failure. Only high IPI patients were at major risk of pro-
gression. At 5 years, the TTP was 54% in high IPI risk
patients, whereas those with low/low-intermediate and
high-intermediate IPI had low rates of progression with
TTP of 87% and 92%, respectively (Figure 1D). Estimates
of EFS and OS revealed similar findings (Figure 1E and F).
Clinical and biological prognostic factors 
The IPI was significantly associated with TTP
(P=0.0085), EFS (P<0.0013) and OS (P<0.0001), which was
all driven by the poorer outcome of high-risk patients.
Biomarkers were also analyzed in tumor tissue from 52
(76%) patients. To accurately determine the prognostic
influence of the cell of origin as defined by the GCB versus
non-GCB (ABC surrogate) subgroups, the 10 patients with
PMBL were excluded; 9 from the IHC group and one from
the group without IHC (Table 1).26 Patients' characteristics
were similar in the groups with and without tissue for
IHC (Table 1). Tissue was analyzed with biomarkers of
cellular differentiation (CD10, LMO2, BCL6, and MUM1),
proliferation (Ki67) and apoptosis inhibition (BCL2), and
categorized as GCB or non-GCB DLBCL by the Hans
method (Table 2).10,14,22 All survival end points were signif-
icantly worse in non-GCB compared to GCB DLBCL,
though both groups performed well (Table 2; Figure 2A
and B). Remarkably, no patients with GCB DLBCL pro-
gressed. To control for error in cell categorization by the
Hans method, we also assessed outcome using individual
markers of cellular differentiation. From 95 to 100% of
patients with tumors that expressed LMO2 or CD10, spe-
cific markers of germinal center differentiation, are free of
progression (Table 2). The less differentiation-specific
markers for GCB and non-GCB DLBCL, BCL6 and
MUM1, respectively, showed similar results (Table 2).
Interestingly, while we observed a significant association
between high tumor proliferation (Ki67 ≥ 60%) and sur-
vival outcomes, this was only seen in patients with non-
GCB DLBCL (Table 2; Figure 2D-F). BCL2 expression was
not associated with any survival outcome measure in the
combined GCB and non-GCB DLBCL groups (Table 2) or
in the non-GCB DLBCL group (data not shown). There
were too few events to construct a meaningful multivari-
ate analysis that included IPI score and biomarkers.
Treatment and toxicity
Toxicity was assessed in all 69 patients on study. Sixty-
three (91%) patients completed all treatment cycles. Fifty
(72%) patients underwent at least one dose escalation to
achieve a nadir ANC below 500/μL, and 65 (94%) patients
achieved the desired pharmacodynamic end point.
Overall, 25 (36%) patients had fever with neutropenia, 5
(7%) of which were grade 4. Platelet and red cell transfu-
sions were administered to 9 (13%) and 21 (30%) patients,
respectively. Gastrointestinal toxicity, such as mucositis or
nausea/vomiting, was infrequent and occurred in no more
than 5 patients. Similarly, there were infrequent cardiac
events, and these only included grade 3 arrhythmia in 4
patients. There was a relatively modest incidence of neu-
ropathy given that vincristine was not capped. Overall,
grade 3 motor or sensory neuropathies occurred in 10
(14%) and 7 (10%) patients, respectively, and one patient
developed grade 4 motor neuropathy. Most patients expe-
rienced significant improvement following treatment.
Grade 3 fatigue was observed in 11 (16%) patients. One
patient died from a brain hemorrhage during the first
cycle.
w.H. wilson et al.
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Table 1. Patients’ characteristics.
Patients’ All patients  Patients with Patients without 
characteristics biomarkers excluding biomarkers
PMBL1 excluding PMBL1
N. % N. % N. %
Total patients 69 - 43 - 16 -
Sex
Male 37 54 24 56 9 56
Histology central review
DLBCL 48 81 37 97 11 100
Aggressive B-cell NOS 1 2 1 3 0 0
PMBL 10 17 - - - -
Missing 10 NA
Median age (range) 58 (23-83) 60 (23-80) 64 (35-83)
> 60 30 43 21 48 9 56
Performance status
ECOG  ≥ 22 14 20 10 23 3 23
Stage
III/IV 41 59 29 67 10 63
LDH
>Normal 50 72 33 77 11 69
Extranodal sites
≥ 2 23 34 15 36 6 38
IPI2
Low/low-intermediate 40 60 24 57 8 50
(0-1)
High-intermediate (3) 13 19 8 19 4 25
High (4-5) 14 21 10 24 4 25
PMBL: primary mediastinal B-cell lymphoma; DLBCL: diffuse large B-cell lymphoma; NOS: not oth-
erwise specified; ECOG: Eastern Cooperative Oncology Group; LDH: lactate dehydrogenase; IPI:
International Prognostic Index. 1No significant difference in distribution of patients’ characteristics
among patients with or without tissue for biomarker analysis. 2Two patients missing values for
number of extra-nodal sites and IPI. 
Discussion 
An important goal of this study was to determine
whether the outcome of the NCI trial of DA-EPOCH-R
could be achieved in a multi-institutional setting.17 Indeed,
the positive outcomes of other single institution studies
using novel chemotherapy in aggressive lymphomas,
including DLBCL, Burkitt's lymphoma and mantle cell
Dose-adjusted EPOCH-R in diffuse large B-cell lymphoma
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Table 2.  Biomarkers in GCB and non-GCB DLBCL and outcome.  
Characteristics N. % 1TTP % 2P 1EFS  % 2P 1OS % 2P
5 years (95% CI) 5 years (95% CI) 5 years  (95% CI)
CD10
<  30% 29 71 0.75 (0.55, 0.87) 0.066 0.66 (0.45, 0.80) 0.027 0.72 (0.52, 0.85) 0.053
≥ 30% 12 29 1.00 (---) 1.00 (---) 1.00 (---)
LMO2
0% 20 49 0.74 (0.48, 0.88) 0.058 0.65 (0.40, 0.82) 0.046 0.75 (0.50, 0.89) 0.197
> 0% 21 51 0.95 (0.71, 0.99) 0.90 (0.67, 0.98) 0.90 (0.67, 0.98)
BCL6
<  30% 22 61 0.76 (0.52, 0.89) 0.198 68 (0.45, 0.83) 0.210 0.77 (0.54, 0.90) 0.497
≥ 30% 14 39 0.93 (0.59, 0.99) 86 (0.54, 0.96) 0.86 (0.54, 0.96 )
MUM1
<  30% 36 88 0.89 (0.72, 0.96) 0.005 83 (0.66, 0.92) 0.001 0.86 (0.70, 0.94) 0.011
≥ 30% 5 12 0.40 (0.05, 0.75) 20 (0.01, 0.58) 0.40 (0.05, 0.75)
Subtype
GCB 18 49 100 (---) 0.008 0.94 (0.65, 0.99) 0.008 0.94 (0.65, 0.99) 0.040
Non-GCB 19 51 0.67 (0.40, 0.83) 0.58 (0.33, 0.76) 0.68 (0.43, 0.84)
Ki65
<  60% 26 65 0.92 (0.72, 0.98) 0.020 0.84 (0.64, 0.94) 0.042 0.88 (0.68, 0.96) 0.062
≥  60% 14 35 0.64 (0.34, 0.83) 0.57 (0.28, 0.78) 0.64 (0.34, 0.83)
BCL2
<  30% 15 36 0.93 (0.61, 0.99) 0.196 0.87 (0.56, 0.96) 0.232 0.86 (0.56, 0.96) 0.465
≥ 30% 27 64 0.77 (0.56, 0.89) 0.70 (0.49, 0.84) 0.78 (0.57, 0.89)
1Kaplan-Meier estimates at 5 years. 2P: two-tailed P value, derived from log rank test based on Kaplan-Meier curves. TTP: time to progression; OS: overall survival; GCB DLBCL: ger-
minal center B-cell diffuse large B-cell lymphoma. 
Figure 1. Kaplan-Meier plots of survival outcomes of all patients. Outcomes are reported at 5 years (95% Confidence Interval (CI)) and CI
range is shown on the curves. (A) PFS 81% (69, 88). (B) EFS 75% (63, 84). (C) OS 84% (73, 91). (D) PFS for IPI risk groups: low/low-inter-
mediate (------------------------) 87% (72, 94), high-intermediate (- - - - - - - - ) 92% (57, 99) and high risk (--- . . --- . . --- ) 54% (25, 76) (P=0.0085).
(E) EFS for IPI risk groups: low/low-intermediate 85% (69, 93), high-intermediate 85% (51, 96) and high risk 43% (18, 66) (P<0.0013). (F)
OS for IPI risk groups: low/low-intermediate 95% (80, 99), high-intermediate 92% (57, 99) and high risk 43% (18, 66) (P<0.0001).
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lymphoma, could not be confirmed by multi-institutional
studies.1,27,28 In the present study, the 5-year TTP and OS
were 81% and 84%, respectively, with no late events.
Notably, the outcome of DA-EPOCH-R was similar in the
low/low-intermediate and high-intermediate IPI groups
with 87% and 92% of patients, respectively, progression
free at 5-years. Patents with high IPI score had the least
favorable outcome with a 5-year TTP of 54%. In the NCI
trial of 72 patients, the 5-year TTP and OS were 79% and
80%, respectively, with a median follow up of 54 months.
The outcome by IPI was also similar in the NCI trial.
Among patients with low/low-intermediate and high IPI,
the 5-year TTP was 90% and 47%, respectively.  Patients
with high-intermediate IPI faired less well in the NCI trial
with a 5-year TTP of 67%, but the results are within the
confidence intervals of the present study.  Notably, in
another study of DA-EPOCH-R in high-intermediate and
high IPI risk DLBCL, the 2-year EFS and OS were of 68%
and 75%, respectively.29 The toxicity profile of DA-
EPOCH-R was similar in the CALGB and NCI trials.17
Overall, 91% and 100% of patients in the CALGB and
NCI trials, respectively, achieved ANC nadirs below 500
cells/mL, which is the pharmacodynamic end point.  The
incidence of fever and neutropenia was also similar and
occurred in 36% and 47% of patients, respectively. The
incidence of gastrointestinal side effects, neuropathy and
fatigue were also similar between the two trials. 
This CALGB trial provides further evidence that DA-
EPOCH-R provides favorable outcomes in DLBCL.
Although there are no comparable therapeutic trials with
R-CHOP, two retrospective studies and four randomized
studies provide outcome results with R-CHOP-based
treatment in untreated DLBCL.4,5,30-33 Among these is a ret-
rospective study from the British Columbia Cancer
Agency of R-CHOP in 152 patients with a median age of
63 years and high-intermediate/high IPI in 49%.33 In this
study, the 3-year progression free survival (defined as
TTP) was 65%. In a follow-up paper, this group reported
the outcome of R-CHOP at a median follow up of 33
months using the standard and a revised IPI score.34 Using
the standard IPI, they reported a 4-year PFS (TTP) of 57%
and 51% for high-intermediate and high-risk patients,
respectively. Among the high-risk patients, DA-EPOCH-R
had a similar TTP of 54%, although with a significantly
longer follow up. In contrast, high-intermediate risk
patients had an excellent TTP of 92% with DA-EPOCH-
R.  It should be noted that this study is limited by its short
2-year median follow up and retrospective study design.
The randomized MabThera International Trial (MInT) of
R-CHOP versus CHOP-like treatments, which included
radiotherapy in approximately half the patients, provides
outcome results for patients aged 60 years and under with
low (0-1) age-adjusted IPI.5 With a median follow up of 34
months, the 4-year EFS was 75% with R-CHOP. Patients
on the DA-EPOCH-R study, however, had a significantly
poorer prognosis with 40% high-intermediate/high IPI
and 43% over the age of 60 years.
Analysis of biomarkers confirm previous findings that
DA-EPOCH-R performs better in GCB compared to non-
GCB DLBCL.17,35 The robustness of these results is sup-
ported by the association of individual markers of cell of
origin and outcome in the present study. Our findings are
also consistent with the study by Lenz et al. that showed
a significant association between outcome and GCB and
W.H. Wilson et al.
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Figure 2. Kaplan-Meier plots of survival outcomes patients with biomarkers. (A) PFS of GCB (-------------------------------) and non-GCB ( - - - - - - - - )
DLBCL (P=0.008). (B) EFS of GCB and non-GCB DLBCL (P=0.008). (C) OS of GCB and non-GCB DLBCL (P=0.04). (D) PFS of Ki67 < 60%
(---------------------------) and Ki67 ≥ 60% ( - - - - - - - - - ) in non-GCB DLBCL (P=0.03). (E) EFS of Ki67 < 60% and Ki67 ≥ 60% in non-GCB DLBCL
(P=0.04). (F) OS of Ki67 < 60% and Ki67 ≥ 60% in non-GCB DLBCL (P=0.05). 
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ABC (i.e. non-GCB by IHC) DLBCL determined by GEP.36
Interestingly, unlike previous results with DA-EPOCH-R,
we observed a significant association between high tumor
proliferation and poorer outcome in the present study.16,17,35
However, the adverse effect of high tumor proliferation
was only present in the non-GCB DLBCL group, which
may explain the discordant results with our earlier trials.
We did not find any association between BCL2 expression
and outcome, which is similar to our previous results.17 It
is now recognized that several mechanisms lead to BCL2
overexpression and confer different prognoses, making it
an unreliable biomarker of outcome.15,37,38
The favorable outcome of GCB DLBCL as identified by
the Hans algorithm in the present study is consistent with
prior findings with DA-EPOCH-R.22 In the NCI phase II
study of DA-EPOCH-R, GCB DLBCL had a 79% PFS at
five years.17 Additionally, a NCI study of DA-EPOCH-R in
HIV-associated DLBCL reported a 5-year PFS of 95% in
patients with GCB DLBCL.35 Other studies employing the
Hans algorithm suggest that GCB DLBCL does not have as
favorable an outcome with R-CHOP.39,40 In a recent study
from the University of Barcelona, 149 patients with newly
diagnosed DLBCL categorized by the Hans algorithm
showed no difference in outcome between GCB and non-
GCB DLBCL with a 5-year PFS of 54% and 52%, respec-
tively.39 Analysis of the RICOVER-60 trial from the
German High-Grade Lymphoma Study Group found a 5-
year survival of approximately 50% and 58%, respective-
ly, for GCB and non-GCB DLBCL.40 Furthermore, a trial
including 131 patients from the University of Nebraska
reported a 3-year EFS of 67% and 52% in GCB and non-
GCB DLBCL, respectively.41
It is worthy of note that most clinical studies that have
used IHC algorithms to categorize DLBCL as GCB or non-
GCB DLBCL have not found any difference in outcome
with R-CHOP based treatments.39-42 However, two clinical
studies that used gene expression profiling (GEP), the gold
standard for molecular classification, have shown differ-
ences in outcome of GCB and ABC DLBCL with R-
CHOP.36,39 The reason for this discordance may be due to
technical variability that might lower accuracy of IHC
classification for GCB and ABC (i.e. non-GCB) DLBCL.43
Nonetheless, studies using IHC algorithms with DA-
EPOCH-R have shown significantly better disease out-
come in GCB compared to non-GCB DLBCL similar to the
results with GEP.17, 35
We hypothesize that the efficacy of DA-EPOCH-R in
GCB-DLBCL may be related to its effect on BCL6.44,45
BCL6 is a key germinal center B-cell transcription factor
that suppresses genes involved in lymphocyte activation,
differentiation, cell cycle arrest (p21 and p27Kip1) and
DNA damage response genes (p53 and ATR).44 In GCB
DLBCL, chromosomal translocations and/or somatic
mutations affecting BCL6 enhance its inhibitory effect on
the apoptotic stress response and promote proliferation,
which are associated with treatment failure.14,44,46-48
Interestingly, inhibition of topoisomerase II leads to
downregulation of BCL6 expression by ubiquitin-mediat-
ed protein degradation and possibly through transcription-
al inhibition.49 This may partially account for the in vitro
finding that sustained exposure of tumor cells to the topoi-
somerase inhibitors, etoposide and doxorubicin, promotes
the p53-p21 pathway and activates the check-point kinase
(Chk2), effects that are inhibited in cells engineered to
over-express BCL6.50,51 The association between topoiso-
merase II inhibition and BCL6 expression raises the
hypothesis that regimens directed against topoisomerase
II may be more effective in GCB DLBCL.  In this regard,
DA-EPOCH-R was designed to inhibit topoisomerase II
through several strategies: incorporating two topoiso-
merase II inhibitors, etoposide and doxorubicin; optimiz-
ing topoisomerase II inhibition through a prolonged 96-h
infusion; and maximizing steady state concentrations
through pharmacodynamic dose adjustment.16
The present study provides the first multi-institutional
evidence that DA-EPOCH-R has a favorable outcome in
newly diagnosed DLBCL, and confirms the biomarker
results from the NCI study. DA-EPOCH-R compares
favorably with historical data with R-CHOP, particularly
for the treatment of GCB DLBCL. An ongoing phase III
trial comparing the outcome of DA-EPOCH-R and R-
CHOP in DLBCL within the GCB and ABC DLBCL
molecular subtypes will provide a definitive comparison
of these regimens (CALGB 50303).
Authorship and Disclosures
The information provided by the authors about contributions from
persons listed as authors and in acknowledgments is available with
the full text of this paper at www.haematologica.org.
Financial and other disclosures provided by the authors using the
ICMJE (www.icmje.org) Uniform Format for Disclosure of
Competing Interests are also available at www.haematologica.org.
Dose-adjusted EPOCH-R in diffuse large B-cell lymphoma
haematologica | 2012; 97(5) 763
References
1. Fisher RI, Gaynor ER, Dahlberg S, Oken
MM, Grogan TM, Mize EM, et al.
Comparison of a standard regimen (CHOP)
with three intensive chemotherapy regi-
mens for advanced non-Hodgkin's lym-
phoma. N Engl J Med. 1993;328(14):1002-6.
2. Pfreundschuh M, Trumper L, Kloess M,
Schmits R, Feller AC, Rudolph C, et al.
Two-weekly or 3-weekly CHOP
chemotherapy with or without etoposide
for the treatment of young patients with
good-prognosis (normal LDH) aggressive
lymphomas: results of the NHL-B1 trial of
the DSHNHL. Blood. 2004;104(3):626-33.
3. Pfreundschuh M, Trumper L, Kloess M,
Schmits R, Feller AC, Rube C, et al. Two-
weekly or 3-weekly CHOP chemotherapy
with or without etoposide for the treat-
ment of elderly patients with aggressive
lymphomas: results of the NHL-B2 trial of
the DSHNHL. Blood. 2004;104(3):634-41.
4. Coiffier B, Lepage E, Briere J, Herbrecht R,
Tilly H, Bouabdallah R, et al. CHOP
chemotherapy plus rituximab compared
with CHOP alone in elderly patients with
diffuse large-B-cell lymphoma. N Engl J
Med. 2002;346(4):235-42.
5. Pfreundschuh M, Trumper L, Osterborg A,
Pettengell R, Trneny M, Imrie K, et al.
CHOP-like chemotherapy plus rituximab
versus CHOP-like chemotherapy alone in
young patients with good-prognosis dif-
fuse large-B-cell lymphoma: a randomised
controlled trial by the MabThera
International Trial (MInT) Group. Lancet
Oncol. 2006;7(5):379-91.
6. Tilly H, Lepage E, Coiffier B, Blanc M,
Herbrecht R, Bosly A, et al. Intensive con-
ventional chemotherapy (ACVBP regimen)
compared with standard CHOP for poor-
prognosis aggressive non-Hodgkin lym-
phoma. Blood. 2003;102(13):4284-9.
7. Tilly H, Mounier N, Lederlin P, Briere J,
Dupriez B, Sebban C, et al. Randomized
comparison of ACVBP and m-BACOD in
the treatment of patients with low-risk
aggressive lymphoma: the LNH87-1 study.
Groupe d'Etudes des Lymphomes de
l'Adulte. J Clin Oncol. 2000;18(6):1309-15.
8. Andre M, Mounier N, Leleu X, Sonet A,
Brice P, Henry-Amar M, et al. Second can-
cers and late toxicities after treatment of
aggressive non-Hodgkin lymphoma with
the ACVBP regimen: a GELA cohort study
on 2837 patients. Blood. 2004;103(4):1222-
8.
9. Bertrand Coiffier CH, Christophe Fermé,
Thierry Jo Molina, Olivier Casasnovas,
Christian Gisselbrecht, Andre Bosly, Guy
Laurent, Franck Morschhauser, Herve
Ghesquieres,  Fabrice Jardin, Serge Bologna,
Christophe Fruchart, Danielle Canioni,
Bernadette Corront, Jean Gabarre,
Christophe Bonnet, Maud Janvier, Herve
Tilly. A Prospective Randomized Study
Comparing Dose Intensive
Immunochemotherapy with R-ACVBP vs
Standard R-CHOP In Younger Patients
with Diffuse Large B-Cell Lymphoma
(DLBCL). Groupe d’Etude Des Lymphomes
De l’Adulte (GELA) Study LNH03-2B. Proc
Am Assoc Heme. 2010;116(21):Abstract
109.
10. Wilson WH. Drug resistance in diffuse large
B-cell lymphoma. Semin Hematol. 2006;
43(4):230-9.
11. Gutierrez M, Chabner BA, Pearson D,
Steinberg SM, Jaffe ES, Cheson BD, et al.
Role of a doxorubicin-containing regimen
in relapsed and resistant lymphomas: an 8-
year follow-up study of EPOCH. J Clin
Oncol. 2000;18(21):3633-42.
12. Moskowitz CH, Schoder H, Teruya-
Feldstein J, Sima C, Iasonos A, Portlock CS,
et al. Risk-adapted dose-dense
immunochemotherapy determined by
interim FDG-PET in Advanced-stage dif-
fuse large B-Cell lymphoma. J Clin Oncol.
2010;28(11):1896-903.
13. Miller TP, Grogan TM, Dahlberg S, Spier
CM, Braziel RM, Banks PM, et al.
Prognostic significance of the Ki-67-
associated proliferative antigen in aggres-
sive non-Hodgkin's lymphomas: a prospec-
tive Southwest Oncology Group trial.
Blood. 1994;83(6):1460-6.
14. Wilson WH, Teruya-Feldstein J, Fest T,
Harris C, Steinberg SM, Jaffe ES, et al.
Relationship of p53, bcl-2, and tumor pro-
liferation to clinical drug resistance in non-
Hodgkin's lymphomas. Blood. 1997;89
(2):601-9.
15. Wilson WH, Grossbard ML, Pittaluga S,
Cole D, Pearson D, Drbohlav N, et al.
Dose-adjusted EPOCH chemotherapy for
untreated large B-cell lymphomas: a phar-
macodynamic approach with high efficacy.
Blood. 2002;99(8):2685-93.
16. Wilson WH, Grossbard ML, Pittaluga S,
Cole D, Pearson D, Drbohlav N, et al.
Dose-adjusted EPOCH chemotherapy for
untreated large B-cell lymphomas: a phar-
macodynamic approach with high efficacy.
Blood. 2002;99(8):2685-93.
17. Wilson WH, Dunleavy K, Pittaluga S,
Hegde U, Grant N, Steinberg SM, et al.
Phase II study of dose-adjusted EPOCH and
rituximab in untreated diffuse large B-cell
lymphoma with analysis of germinal center
and post-germinal center biomarkers. J Clin
Oncol. 2008;26(16):2717-24.
18. Wilson WH, Bryant G, Bates S, Fojo A,
Wittes RE, Steinberg SM, et al. EPOCH
chemotherapy: toxicity and efficacy in
relapsed and refractory non-Hodgkin's
lymphoma. J Clin Oncol. 1993;11(8):1573-
82.
19. Feugier P, Van Hoof A, Sebban C, Solal-
Celigny P, Bouabdallah R, Ferme C, et al.
Long-term results of the R-CHOP study in
the treatment of elderly patients with dif-
fuse large B-cell lymphoma: a study by the
Groupe d'Etude des Lymphomes de
l'Adulte. J Clin Oncol. 2005;23(18):4117-26.
20. Cheson BD, Horning SJ, Coiffier B, Shipp
MA, Fisher RI, Connors JM, et al. Report of
an international workshop to standardize
response criteria for non-Hodgkin's lym-
phomas. J Clin Oncol. 1999;17(4):1244.
21. Crowther D, Lister TA. The Cotswolds
report on the investigation and staging of
Hodgkin's disease. Br J Cancer. 1990;62
(4):551-2.
22. Hans CP, Weisenburger DD, Greiner TC,
Gascoyne RD, Delabie J, Ott G, et al.
Confirmation of the molecular classifica-
tion of diffuse large B-cell lymphoma by
immunohistochemistry using a tissue
microarray. Blood. 2004;103(1):275-82.
23. Kaplan E, Meier P. Nonparametric estima-
tion from incomplete observations. Journal
of the American Statistical Association.
1958;53:457-81.
24. Mantel N. Evaluation of survival data and
two new rank order statistics arising in its
consideration. Cancer Chemotherapy
Reports. 1966;50:163-70.
25. [No authors listed]. A predictive model for
aggressive non-Hodgkin’s lymphoma. The
International Non-Hodgkin’s Lymphoma
Prognostic Factors Project. N Engl J Med.
1993;329(14):987-94.
26. Alizadeh AA, Eisen MB, Davis RE, Ma C,
Lossos IS, Rosenwald A, et al. Distinct
types of diffuse large B-cell lymphoma
identified by gene expression profiling.
Nature. 2000;403(6769):503-11.
27. Mead GM, Sydes MR, Walewski J, Grigg A,
Hatton CS, Pescosta N, et al. An interna-
tional evaluation of CODOX-M and
CODOX-M alternating with IVAC in adult
Burkitt's lymphoma: results of United
Kingdom Lymphoma Group LY06 study.
Ann Oncol. 2002;13(8):1264-74.
28. EM Epner, Unger J, Miller T, Rimsza L,
Spier C, LeBlanc M, Fisher R. A multi center
trial of hyperCVAD+rituxan in patients
with newly diagnosed mantle cell lym-
phoma. Blood. 2007;110(11):387.
29. Garcia-Suarez J, Banas H, Arribas I, De
Miguel D, Pascual T, Burgaleta C. Dose-
adjusted EPOCH plus rituximab is an effec-
tive regimen in patients with poor-prognos-
tic untreated diffuse large B-cell lymphoma:
results from a prospective observational
study. Br J Haematol. 2007;136(2):276-85.
30. Habermann TM, Weller EA, Morrison VA,
Gascoyne RD, Cassileth PA, Cohn JB, et al.
Rituximab-CHOP Versus CHOP Alone or
With Maintenance Rituximab in Older
Patients With Diffuse Large B-Cell
Lymphoma. J Clin Oncol. 2006;24(19):
3121-7.
31. Pfreundschuh M, Schubert J, Ziepert M,
Schmits R, Mohren M, Lengfelder E, et al.
Six versus eight cycles of bi-weekly CHOP-
14 with or without rituximab in elderly
patients with aggressive CD20+ B-cell lym-
phomas: a randomised controlled trial
(RICOVER-60). Lancet Oncol. 2008;9(2):
105-16.
32. Gang AO, Strom C, Pedersen M, d'Amore
F, Pedersen LM, Bukh A, et al. R-CHOEP-14
improves overall survival in young high-
risk patients with diffuse large B-cell lym-
phoma compared with R-CHOP-14. A
population-based investigation from the
Danish Lymphoma Group. Ann Oncol.
2012;23(1):147-53.
33. Sehn LH, Donaldson J, Chhanabhai M,
Fitzgerald C, Gill K, Klasa R, et al.
Introduction of combined CHOP plus rit-
uximab therapy dramatically improved
outcome of diffuse large B-cell lymphoma
in British Columbia. J Clin Oncol.
2005;23(22):5027-33.
34. Sehn LH, Berry B, Chhanabhai M,
Fitzgerald C, Gill K, Hoskins P, et al. The
revised International Prognostic Index (R-
IPI) is a better predictor of outcome than
the standard IPI for patients with diffuse
large B-cell lymphoma treated with R-
CHOP. Blood. 2007;109(5):1857-61.
35. Dunleavy K, Little RF, Pittaluga S, Grant N,
Wayne AS, Carrasquillo JA, et al. The role
of tumor histogenesis, FDG-PET, and short-
course EPOCH with dose-dense rituximab
(SC-EPOCH-RR) in HIV-associated diffuse
large B-cell lymphoma. Blood.
2010;115(15):3017-24.
36. Lenz G, Wright G, Dave SS, Xiao W, Powell
J, Zhao H, et al. Stromal gene signatures in
large-B-cell lymphomas. N Engl J Med.
2008;359(22):2313-23.
37. Rosenwald A, Wright G, Chan WC,
Connors JM, Campo E, Fisher RI, et al. The
use of molecular profiling to predict sur-
vival after chemotherapy for diffuse large-
B-cell lymphoma. N Engl J Med.
2002;346(25):1937-47.
38. Iqbal J, Sanger WG, Horsman DE,
Rosenwald A, Pickering DL, Dave B, et al.
BCL2 Translocation Defines a Unique
Tumor Subset within the Germinal Center
B-Cell-Like Diffuse Large B-Cell
Lymphoma. Am J Pathol. 2004;165(1):159-
66.
39. Gutierrez-Garcia G, Cardesa-Salzmann T,
Climent F, Gonzalez-Barca E, Mercadal S,
Mate JL, et al. Gene expression profiling
and not immunophenotypic algorithms
predicts prognosis in patients with diffuse
large B-cell lymphoma treated with
immunochemotherapy. Blood. 2011;117
(18):4836-43. 
40. Ott G, Ziepert M, Klapper W, Horn H,
Szczepanowski M, Bernd HW, et al.
Immunoblastic morphology but not the
immunohistochemical GCB/nonGCB clas-
sifier predicts outcome in diffuse large B-
cell lymphoma in the RICOVER-60 trial of
the DSHNHL. Blood. 2010;116(23):4916-
25.
41. Fu K, Weisenburger DD, Choi WW, Perry
KD, Smith LM, Shi X, et al. Addition of rit-
uximab to standard chemotherapy
improves the survival of both the germinal
center B-cell-like and non-germinal center
B-cell-like subtypes of diffuse large B-cell
lymphoma. J Clin Oncol. 2008;26(28):4587-
94.
42. Rayman N, Lam KH, van der Holt B, Koss
C, Veldhuizen D, Budel LM, et al.
Prognostic Relevance of
Immunohistochemical Subclassification of
Diffuse Large B-Cell Lymphoma in Two
Prospective Phase III Clinical Trials. Clin
Lymphoma Myeloma Leuk. 2011;11(1):23-
32.
43. de Jong D, Rosenwald A, Chhanabhai M,
Gaulard P, Klapper W, Lee A, et al.
Immunohistochemical Prognostic Markers
in Diffuse Large B-Cell Lymphoma:
Validation of Tissue Microarray As a
Prerequisite for Broad Clinical
Applications--A Study From the Lunenburg
Lymphoma Biomarker Consortium. J Clin
Oncol. 2007;25(7):805-12.
44. Phan RT, Dalla-Favera R. The BCL6 proto-
oncogene suppresses p53 expression in ger-
minal-centre B cells. Nature. 2004;432
w.H. wilson et al.
764 haematologica | 2012; 97(5)
(7017):635-9.
45. Phan RT, Saito M, Basso K, Niu H, Dalla-
Favera R. BCL6 interacts with the transcrip-
tion factor Miz-1 to suppress the cyclin-
dependent kinase inhibitor p21 and cell
cycle arrest in germinal center B cells. Nat
Immunol. 2005;6(10):1054-60.
46. Paik JH, Jeon YK, Park SS, Kim YA, Kim JE,
Huh J, et al. Expression and prognostic
implications of cell cycle regulatory mole-
cules, p16, p21, p27, p14 and p53 in germi-
nal centre and non-germinal centre B-like
diffuse large B-cell lymphomas.
Histopathology. 2005;47(3):281-91.
47. Ranuncolo SM, Polo JM, Dierov J, Singer
M, Kuo T, Greally J, et al. Bcl-6 mediates
the germinal center B cell phenotype and
lymphomagenesis through transcriptional
repression of the DNA-damage sensor
ATR. Nat Immunol. 2007;8(7):705-14.
48. Pasqualucci L, Migliazza A, Basso K,
Houldsworth J, Chaganti RS, Dalla-Favera
R. Mutations of the BCL6 proto-oncogene
disrupt its negative autoregulation in dif-
fuse large B-cell lymphoma. Blood.
2003;101(8):2914-23.
49. Kurosu T, Fukuda T, Miki T, Miura O.
BCL6 overexpression prevents increase in
reactive oxygen species and inhibits apop-
tosis induced by chemotherapeutic
reagents in B-cell lymphoma cells.
Oncogene. 2003;22(29):4459-68.
50. Theard D, Coisy M, Ducommun B,
Concannon P, Darbon J-M. Etoposide and
Adriamycin but Not Genistein Can
Activate the Checkpoint Kinase Chk2
Independently of ATM/ATR. Biochemical
and Biophysical Research
Communications. 2001;289(5):1199-204.
51. Siu WY, Lau A, Arooz T, Chow JPH, Ho
HTB, Poon RYC. Topoisomerase poisons
differentially activate DNA damage check-
points through ataxia-telangiectasia mutat-
ed-dependent and -independent mecha-
nisms. Mol Cancer Ther. 2004;3(5):621-32.
Dose-adjusted EPOCH-R in diffuse large B-cell lymphoma
haematologica | 2012; 97(5) 765
